Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.51 |
| ▸ | EGFR | P00533 | 5/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5806798 | 0.98 | MAOB (0.50) | MAOBEGFRERBB2IDO1AGXT | |
| SCHEMBL5067092 | 0.89 | GRIA2 (0.44) | MAOBEGFRERBB2IDO1AGXT | |
| SCHEMBL11268668 | 0.85 | EGFR (0.49) | MAOBEGFRERBB2MAOATAAR1 | |
| SCHEMBL6509671 | 0.85 | ALDH1A1 (0.46) | — | |
| SCHEMBL15505045 | 0.85 | EGFR (0.51) | MAOBEGFRERBB2MAOATAAR1 | |
| SCHEMBL9294120 | 0.83 | TAAR1 (0.50) | MAOBEGFRERBB2IDO1AGXT | |
| SCHEMBL1448505 | 0.83 | EGFR (0.53) | MAOBEGFRERBB2IDO1AGXT | |
| SCHEMBL78652 | 0.82 | AKR1B1 (0.58) | EGFRERBB2TAAR1 | |
| SCHEMBL1357383 | 0.82 | EGFR (0.51) | MAOBEGFRERBB2IDO1AGXT | |
| SCHEMBL4234560 | 0.81 | ALDH1A1 (0.60) | MAOBMAOATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103012098-A | Fluorene derivative and preparation method thereof | UNIV EAST CHINA NORMAL | 2013-04-03 | — | — | CN | claimed |
| US-12441726-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| CN-119219548-A | Allyl carbazole ketoxime ester compound, product containing same and application thereof | 维思普新材料（苏州）有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-115297861-B | Compounds and uses thereof | 福宏治疗公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117402081-A | Aryl substituted amine derivative, preparation method and application thereof | 南京医科大学 | 2024-01-16 | — | — | CN | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4149928-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | Metabomed Ltd (IL) | 2023-03-22 | — | — | EP | disclosed |
| CN-112939829-B | Synthetic method of aryl trifluoromethyl thioether | 武汉药明康德新药开发有限公司 | 2023-02-21 | — | — | CN | disclosed |
| CN-115650830-A | Method for preparing alpha-substituted methyl ketone from terminal olefin | 长沙资材科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | MERCK SHARP & DOHME LLC | 2004-03-25 | — | — | US | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
| WO-2003086288-A2 | BICYCLIC AMIDES | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087037-A1 | SUBSTITUTED ARYL AMIDES | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003082190-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003077847-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
| US-5639780-A | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1997-06-17 | — | — | US | disclosed |
| WO-1996037467-A1 | N-BENZYLINDOL-3-YL BUTANOIC ACID DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441726-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | MAOB 975/4885EGFR 4146/4885ERBB2 3438/4885 |
| US-20040058820-A1 | Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis | CNR1, CNR2, MAG | MAOB 597/4885EGFR 1529/4885ERBB2 2199/4885 |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | MAOB 975/4885EGFR 4146/4885ERBB2 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.